Details of the Drug Combinations

General Information of This Drug (ID: DMPRI8G)

• Drug Name: Buprenorphine (DMPRI8G)
• Synonyms: Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M

Indication

Opioid dependence; ICD 11: 6C43.2Z; Status: Approved [1]; Pain; ICD 11: MG30-MG3Z; Status: Approved [2]; Psychiatric disorder; ICD 11: 6E8Z; Status: Phase 3 [3]; Migraine; ICD 11: 8A80; Status: Phase 2 [4]; Chronic pain; ICD 11: MG30; Status: Investigative [1]

• Therapeutic Class: Analgesics
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

13 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Buprenorphine + Morphine	DCF0SLE	Morphine	Opioid Abuse	[5]
Buprenorphine + Methadone	DCVMM8X	Methadone	Substance-related Disorders	[6]
Buprenorphine + Venlafaxine	DCR41AO	Venlafaxine	Major Depressive Disorder	[7]
Buprenorphine + Naltrexone	DCRABL2	Naltrexone	ECG Effects	[8]
Dexamethasone + Buprenorphine	DCU26BD	Dexamethasone	Postoperative Pain	[9]
Lopinavir + Buprenorphine	DC13ZKW	Lopinavir	HIV Infections	[10]
Rifabutin + Buprenorphine	DCCQ0P8	Rifabutin	Opioid Dependency	[11]
Rifampicin + Buprenorphine	DC7U9JS	Rifampicin	Opioid Dependency	[11]
Buprenorphine + Tramadol	DCMT3Q9	Tramadol	Head and Neck Squamous Cell Carcinoma	[12]
Buprenorphine + Buprenorphine	DCJG3RL	Buprenorphine	Back Pain Lower Back Chronic	[13]
Buprenorphine + Naltrexone	DCRW42T	Naltrexone	Opioid Use Disorder	[14]
Buprenorphine + Acetaminophen	DCKJVA2	Acetaminophen	Depression	[15]
Olanzapine + Buprenorphine	DC48Q2N	Olanzapine	Suicide Crisis Syndrome	[16]

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Naloxone + Buprenorphine	DCRY2XX	Naloxone	Opioid dependence; Major depressive disorder	[17]

References

• [1] Buprenorphine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1670).
• [3] ClinicalTrials.gov (NCT02510014) Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder.
• [4] ClinicalTrials.gov (NCT00941304) Study of BEMA Buprenorphine in the Treatment of Dental Pain. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01136356) A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
• [6] ClinicalTrials.gov (NCT01560221) Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution
• [7] ClinicalTrials.gov (NCT02263248) Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
• [8] ClinicalTrials.gov (NCT01999114) The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers
• [9] ClinicalTrials.gov (NCT02198235) Prolonged Popliteal Fossa Nerve Blockade (Prolonged Pop)
• [10] ClinicalTrials.gov (NCT00571961) Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
• [11] ClinicalTrials.gov (NCT00877591) Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications
• [12] ClinicalTrials.gov (NCT04752384) Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients
• [13] ClinicalTrials.gov (NCT01125917) Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015
• [14] ClinicalTrials.gov (NCT02696434) Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
• [15] ClinicalTrials.gov (NCT02267057) Efficacy of Pain Treatment on Depression in Patients With Dementia
• [16] ClinicalTrials.gov (NCT06133114) Psychopharmacological Treatment of Emotional Distress
• [17] FDA Drug Development and Drug Interactions